Aliases & Classifications for Mammographic Density

MalaCards integrated aliases for Mammographic Density:

Name: Mammographic Density 56 71

External Ids:

OMIM 56 607308
UMLS 71 C1846502

Summaries for Mammographic Density

MalaCards based summary : Mammographic Density is related to insulin-like growth factor i and in situ carcinoma. An important gene associated with Mammographic Density is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are Cytochrome P450 - arranged by substrate type and Relaxin signaling pathway. The drugs Vitamin D and Trace Elements have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and bone, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Wikipedia : 74 Breast cancer screening is the medical screening of asymptomatic, apparently healthy women for breast... more...

More information from OMIM: 607308

Related Diseases for Mammographic Density

Diseases related to Mammographic Density via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 204)
# Related Disease Score Top Affiliating Genes
1 insulin-like growth factor i 30.5 PRL IGFBP3 IGF1 ESR1
2 in situ carcinoma 30.4 PGR ESR1 CYP19A1
3 ductal carcinoma in situ 30.3 PGR ESR1 CYP19A1
4 lobular neoplasia 29.8 PGR ESR1 CYP19A1
5 sporadic breast cancer 29.8 PGR ESR1 CYP19A1
6 hypertrophy of breast 29.6 PGR ESR1 CYP19A1
7 amenorrhea 29.4 PRL IGF1 CYP19A1 CYP17A1
8 endometrial hyperplasia 29.3 PGR ESR1 CYP19A1 CYP17A1
9 female breast cancer 28.6 PGR IGF1 ESR1 CYP1A1 CYP19A1
10 breast disease 27.6 PRL PGR IGFBP3 IGF1 ESR1 CYP1B1
11 endometriosis 27.3 PGR HSD17B1 ESR1 CYP1B1 CYP1A1 CYP19A1
12 breast cancer 27.0 PRL PGR IGFBP3 IGF1 HSD17B1 ESR1
13 body mass index quantitative trait locus 1 10.5
14 slipped capital femoral epiphysis 10.4 IGFBP3 IGF1
15 secondary adrenal insufficiency 10.4 IGFBP3 IGF1
16 galactorrhea 10.4 PRL IGF1
17 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 10.4 IGFBP3 IGF1
18 traumatic brain injury 10.4 IGF1 COMT
19 brain injury 10.4 IGF1 COMT
20 pituitary infarct 10.3 PRL IGF1
21 acidophil adenoma 10.3 PRL IGF1
22 marasmus 10.3 IGFBP3 IGF1
23 hormone producing pituitary cancer 10.3 PRL IGF1
24 mixed epithelial stromal tumour 10.3 CYP1B1 COMT
25 fetal macrosomia 10.3 IGFBP3 IGF1
26 sheehan syndrome 10.3 PRL IGF1
27 acid-labile subunit deficiency 10.3 IGFBP3 IGF1
28 pituitary apoplexy 10.3 PRL IGF1
29 hypothalamic obesity 10.3 IGF1 HSD17B1
30 donohue syndrome 10.2 IGFBP3 IGF1
31 schizophreniform disorder 10.2 PRL COMT
32 postmenopausal atrophic vaginitis 10.2 ESR1 CYP19A1
33 salpingitis isthmica nodosa 10.2 PRL CYP1B1
34 pseudohypoparathyroidism, type ia 10.2 PRL IGF1
35 pseudovaginal perineoscrotal hypospadias 10.2 IGFBP3 CYP17A1
36 glassy cell carcinoma of the cervix 10.2 PGR ESR1
37 bartholin's gland adenoid cystic carcinoma 10.2 PGR ESR1
38 chronic tympanitis 10.2 PGR ESR1
39 bartholin's gland adenoma 10.2 PGR ESR1
40 granulomatous endometritis 10.2 PGR ESR1
41 bartholin's gland benign neoplasm 10.2 PGR ESR1
42 vestibular gland benign neoplasm 10.2 PGR ESR1
43 pituitary tumors 10.2 PRL IGF1
44 uterine corpus adenosarcoma 10.2 PGR ESR1
45 adenosarcoma 10.2 PGR ESR1
46 vaginal glandular tumor 10.2 PGR ESR1
47 lung leiomyoma 10.2 PGR ESR1
48 vulvar syringoma 10.2 PGR ESR1
49 trigonitis 10.2 PGR ESR1
50 hypoactive sexual desire disorder 10.2 PRL CYP19A1

Graphical network of the top 20 diseases related to Mammographic Density:



Diseases related to Mammographic Density

Symptoms & Phenotypes for Mammographic Density

Clinical features from OMIM:

607308

MGI Mouse Phenotypes related to Mammographic Density:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 COMT CYP17A1 CYP19A1 ESR1 HSD17B1 IGFBP3
2 endocrine/exocrine gland MP:0005379 9.91 COMT CYP19A1 CYP1A1 ESR1 HSD17B1 IGF1
3 homeostasis/metabolism MP:0005376 9.9 COMT CYP17A1 CYP19A1 CYP1A1 CYP1B1 ESR1
4 cardiovascular system MP:0005385 9.87 COMT CYP17A1 CYP19A1 ESR1 IGF1 IGFBP3
5 adipose tissue MP:0005375 9.8 CYP17A1 CYP19A1 ESR1 IGF1 IGFBP3
6 neoplasm MP:0002006 9.35 CYP1B1 ESR1 IGF1 PGR PRL
7 reproductive system MP:0005389 9.23 COMT CYP17A1 CYP19A1 ESR1 HSD17B1 IGF1

Drugs & Therapeutics for Mammographic Density

Drugs for Mammographic Density (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 113)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
2 Trace Elements Phase 3
3 Nutrients Phase 3
4 Micronutrients Phase 3
5 Calciferol Phase 3
6 3,4-dihydroxyphenylethanol Phase 2, Phase 3
7 Olive Phase 2, Phase 3
8 Anti-Infective Agents Phase 2, Phase 3
9 Antioxidants Phase 2, Phase 3
10 Platelet Aggregation Inhibitors Phase 2, Phase 3
11 Protective Agents Phase 2, Phase 3
12
Atorvastatin Approved Phase 2 134523-00-5 60823
13
Tamoxifen Approved Phase 2 10540-29-1 2733526
14
Metformin Approved Phase 2 657-24-9 14219 4091
15
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
16
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
17
Calcium carbonate Approved, Investigational Phase 2 471-34-1
18
Denosumab Approved Phase 2 615258-40-7
19
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
20
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
21
Lovastatin Approved, Investigational Phase 2 75330-75-5 53232
22
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
23
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2 83-88-5 493570
24
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
25
Epigallocatechin gallate Investigational Phase 2 989-51-5 65064
26
Epigallocatechin Experimental, Investigational Phase 2 970-74-1 72277
27
Epicatechin Investigational Phase 2 490-46-0, 35323-91-2 72276
28
Afimoxifene Investigational Phase 2 68392-35-8
29 Estrogens Phase 2
30 Hormone Antagonists Phase 2
31 Hormones Phase 2
32 Hypoglycemic Agents Phase 2
33 Aromatase Inhibitors Phase 2
34 Tea Phase 2
35 Catechol Phase 2
36 Gastrointestinal Agents Phase 2
37 Antacids Phase 2
38 Anti-Ulcer Agents Phase 2
39 Antineoplastic Agents, Hormonal Phase 2
40 Estrogen Receptor Antagonists Phase 2
41 Estrogen Antagonists Phase 2
42 Estrogen Receptor Modulators Phase 2
43 Pharmaceutical Solutions Phase 2
44 Hydroxytamoxifen Phase 2
45 Vitamins Phase 2
46 Calcium, Dietary Phase 2
47 Soy Bean Phase 2
48 Phytoestrogens Phase 2
49 Vitamin B2 Phase 2
50 Cyclooxygenase 2 Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial Active, not recruiting NCT01315015 Phase 4
2 Vitamin D and Breast Cancer Biomarkers Completed NCT01224678 Phase 3
3 An Explanatory Clinical Trial of Breast Cancer Prevention Completed NCT00148057 Phase 3
4 A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer Recruiting NCT02068092 Phase 2, Phase 3 Hydroxytyrosol
5 Statins and Breast Cancer Biomarkers Unknown status NCT00914017 Phase 2 Atorvastatin;Placebo
6 A Randomized, Open Pilot Study to Investigate the Mammographic Density Reduction on Healthy Women, Within the Karma Cohort, for Two Different Doses of Tamoxifen Completed NCT04079517 Phase 1, Phase 2 Tamoxifen
7 A Randomised, Double Blinded, Six-armed Placebo Controlled Study to Investigate Optimal Dose of Tamoxifen With the Most Favourable Side Effect Spectre and With Mammography Density Reduction Non-inferior to That of 20 mg Tamoxifen (Karisma 2) Completed NCT03346200 Phase 2 Tamoxifen Oral Tablet;Placebo Oral Tablet
8 Phase II, Randomized,Double-blind, Placebo-controlled, Study of the Efficacy of Green Tea Extract on Biomarkers of Breast Cancer Risk in High Risk Women With Differing Catechol-O-methyl Transferase (COMT) Genotypes Completed NCT00917735 Phase 2 Green tea extract supplement
9 Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer Completed NCT01589367 Phase 2 Metformin;Placebo
10 Cancer Risk and Biomarkers of Tamoxifen Chemoprevention Completed NCT00295100 Phase 2 Tamoxifen
11 A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer Completed NCT00056082 Phase 2 celecoxib
12 A Trial of Exemestane in Postmenopausal Women With DCIS or at High Risk for Invasive Breast Cancer Completed NCT00073073 Phase 2 Exemestane
13 Randomized Clinical Trial of RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT) Recruiting NCT04067726 Phase 2 Denosumab;Placebo;Calcium;Vitamin D3
14 A Randomized, Double-Blind, Placebo-Controlled Study of 4-hydroxytamoxifen Topical Gel in Women With Mammographically Dense Breast Recruiting NCT03063619 Phase 2 Afimoxifene
15 Mammographic Density and Soy Isoflavones Active, not recruiting NCT00204490 Phase 2
16 Randomized Placebo-Controlled Biomarker Modulation Trial Using Celecoxib in Premenopausal Women at High Risk for Breast Cancer Terminated NCT00088972 Phase 2 celecoxib
17 A Phase 2 Trial of Lovastatin for Modification of Abnormal Breast Duct Cytology and Risk-Associated Biomarkers in Women at High Inherited Risk of Breast Cancer Terminated NCT00285857 Phase 2 Lovastatin
18 A Single-Centre Pilot Trial Investigating the Efficacy and Safety of Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density Completed NCT03264651 Phase 1 enobosarm
19 A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole From Subcutaneous Testosterone and Anastrozole (T+Ai) in Premenopausal Women Completed NCT03314298 Phase 1 testosterone anastrozole
20 Pilot Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer Completed NCT00976339 Phase 1 Cholecalciferol
21 Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer Completed NCT00516243 Phase 1 defined green tea catechin extract
22 A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived From Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R) in Patients With Breast Cancer Active, not recruiting NCT02780401 Phase 1
23 Change in Mammographic Density With Metformin Use: A Companion Study to NCIC Study MA.32 Unknown status NCT01666171 metformin hydrochloride
24 THE EFFECTS OF VITAMIN D ON MAMMOGRAPHIC DENSITY AND BREAST TISSUE Unknown status NCT02239874
25 The British Breast Cancer Study - National Cancer Research Network Cohort (BBC-NCRN) Unknown status NCT00896818
26 Total Xenoestrogen Body Burden in Relation to Mammographic Density, a Marker of Breast Cancer Risk Completed NCT00839696
27 Pilot Study to Examine Histological Characteristics of Mammographic Density With Molecular Breast Imaging: Part 2 - Premenopausal Women Completed NCT01588834
28 Mammographic Density and the Risk of Tumor Recurrence in Asian Women: a Case-control Study Completed NCT02771665
29 KEEPS Mammographic Density And Breast Health Ancillary Study Completed NCT02524561 CEE pill;Estradiol patch;Active Progesterone
30 Longitudinal Changes in Mammographic Density and Risk of Breast Cancer Completed NCT00445445
31 Genetics of Mammographic Appearances and Patterns (The GenMap Study) Completed NCT01160510
32 The Effects of Adjuvant Zoladex Plus Tamoxifen on Breast Density in Pre- or Peri-menopausal Women With Early-stage Breast Cancer Completed NCT00827307 tamoxifen;Goserelin
33 Transillumination for Breast Cancer Risk Assessment Completed NCT00188721
34 Alberta Physical Activity and Breast Cancer Prevention (ALPHA) Trial Completed NCT00522262
35 Phase IIB Randomized Controlled Biomarker Modulation Study of Vitamin D in Premenopausal Women at High Risk for Breast Cancer Completed NCT01097278
36 Pilot Trial to Identify and Characterize Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer Completed NCT00923377
37 RANKL Inhibition and Breast Tissue Biomarkers in Premenopausal Women With Dense Breasts Completed NCT03629717 Early Phase 1 Denosumab;Calcium;Vitamin D
38 The Ultrasound Study of Tamoxifen Completed NCT01582074
39 The Effect of Aspirin on Mammogram Density (TEAM) Completed NCT00470561 Aspirin;Placebo
40 Evaluation of Changes in Mammographic Breast Density Associated With Bazedoxifene, Raloxifene, and Placebo in Postmenopausal Women: An Ancillary Study of Protocol 3068A1-301-WW Completed NCT00418236
41 Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D Completed NCT01166763 vitamin D3
42 A Randomized Study Of The Effect Of Exemestane (Aromasin) Versus Placebo On Breast Density In Postmenopausal Women At Increased Risk For Development Of Breast Cancer Completed NCT00066586 exemestane;Placebo
43 Combination of Low Dose Antiestrogens With Omega-3 Fatty Acids for Prevention of Hormone-independent Breast Cancer Completed NCT00723398 Raloxifene 60 Mg Oral Tablet;Raloxifene 30 Mg Oral Tablet;Lovaza 4gm & Raloxifene 30mg
44 Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Pilot Study Completed NCT00006425
45 Exercise Diet and Sex Hormones in Postmenopausal Women (NEW) Completed NCT00470119
46 Intervention Program to Promote Changes in Diet and Physical Activity and to Evaluate Its Impact on Body Weight, Biomarkers of Disease and Quality of Life in Breast Cancer Survivors Completed NCT04096469
47 Improving Cancer-Related Outcomes in Shift Workers Completed NCT02609373
48 A Study of Breast Cancer, Breast Disease, Mammographic Density and Pesticides Among a Population From Triana, Alabama Completed NCT00341315
49 Breast Imaging Screening Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-up Study Completed NCT00006421
50 Breast Cancer and Insulin Resistance: Implications for Preventive Counseling in Familial and Sporadic Cases Completed NCT00304941

Search NIH Clinical Center for Mammographic Density

Genetic Tests for Mammographic Density

Anatomical Context for Mammographic Density

MalaCards organs/tissues related to Mammographic Density:

40
Breast, Testes, Bone, Liver, Thyroid, Skin, Pituitary

Publications for Mammographic Density

Articles related to Mammographic Density:

(show top 50) (show all 1154)
# Title Authors PMID Year
1
Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. 56 61
26073781 2015
2
Common variants in ZNF365 are associated with both mammographic density and breast cancer risk. 61 56
21278746 2011
3
Heritability of mammographic density, a risk factor for breast cancer. 61 56
12239257 2002
4
Evaluation of LIBRA Software for Fully Automated Mammographic Density Assessment in Breast Cancer Risk Prediction. 61
32396041 2020
5
Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden. 61
32563178 2020
6
Key steps for effective breast cancer prevention. 61
32528185 2020
7
Hormone replacement therapy and mammographic density: a systematic literature review. 61
32572713 2020
8
Adolescent caffeine consumption and mammographic breast density in premenopausal women. 61
31152213 2020
9
Comparing recall rates following implementation of digital breast tomosynthesis to synthetic 2D images and digital mammography on women with breast-conserving surgery. 61
32529566 2020
10
Radiological audit of interval breast cancers: Estimation of tumour growth rates. 61
32298962 2020
11
What are the benefits and harms of risk stratified screening as part of the NHS breast screening Programme? Study protocol for a multi-site non-randomised comparison of BC-predict versus usual screening (NCT04359420). 61
32552763 2020
12
No association between night shiftwork and mammographic density. 61
32467312 2020
13
Is mammographic density a marker of breast cancer phenotypes? 61
32410205 2020
14
Risk-based breast cancer screening strategies in women. 61
31848103 2020
15
Alcohol and Tobacco Use in Relation to Mammographic Density in 23,456 Women. 61
32066618 2020
16
Automated mammographic density measurement using Quantra™: comparison with the Royal Australian and New Zealand College of Radiology synoptic scale. 61
32509917 2020
17
Assessing breast cancer risk within the general screening population: developing a breast cancer risk model to identify higher risk women at mammographic screening. 61
32358648 2020
18
Age-Specific Breast Density Changes in Taiwanese Women: A Cross-Sectional Study. 61
32375295 2020
19
Impact of Background Parenchymal Enhancement on Diagnostic Performance in Screening Breast MRI. 61
31327575 2020
20
A case-control evaluation of 143 single nucleotide polymorphisms for breast cancer risk stratification with classical factors and mammographic density. 61
31251818 2020
21
Annual vs Biennial Screening: Diagnostic Accuracy Among Concurrent Cohorts Within the Ontario Breast Screening Program. 61
31233138 2020
22
Organoid model of mammographic density displays a higher frequency of aberrant colony formations with radiation exposure. 61
31778145 2020
23
Mammographic Density Change and Risk of Breast Cancer. 61
31298705 2020
24
Determinants of Mammographic Breast Density by Race Among a Large Screening Population. 61
32373777 2020
25
A Review of Breast Density Implications and Breast Cancer Screening. 61
32334975 2020
26
Breast Mammographic Density: Stromal Implications on Breast Cancer Detection and Therapy. 61
32178425 2020
27
Ductal Carcinoma In Situ of the Breast: An Update with Emphasis on Radiological and Morphological Features as Predictive Prognostic Factors. 61
32155777 2020
28
YY1 is a cis-regulator in the organoid models of high mammographic density. 61
31688895 2020
29
Inclusion of Endogenous Plasma Dehydroepiandrosterone Sulfate and Mammographic Density in Risk Prediction Models for Breast Cancer. 61
31948996 2020
30
Factors associated with MRI detection of occult lesions in newly diagnosed breast cancers. 61
31984517 2020
31
In utero DDT exposure and breast density before age 50. 61
31711904 2020
32
The relationship of breast density in mammography and magnetic resonance imaging in women with triple negative breast cancer. 61
31927471 2020
33
Breast Density Notification: An Australian Perspective. 61
32138307 2020
34
Stratification of Breast Cancer Risk in Terms of the Influence of Age and Mammographic density. 61
32106324 2020
35
Multi-View Mammographic Density Classification by Dilated and Attention-Guided Residual Learning. 61
32012021 2020
36
Going Beyond Conventional Mammographic Density to Discover Novel Mammogram-Based Predictors of Breast Cancer Risk. 61
32110975 2020
37
Association of Imaging-Based Body Fat Distribution and Mammographic Density in the Multiethnic Cohort Adiposity Phenotype Study. 61
31727725 2020
38
Comparison of a Deep Learning Risk Score and Standard Mammographic Density Score for Breast Cancer Risk Prediction. 61
31845842 2020
39
Early-Life and Adult Anthropometrics in Relation to Mammographic Image Intensity Variation in the Nurses' Health Studies. 61
31826913 2020
40
Continuous tumour growth models, lead time estimation and length bias in breast cancer screening studies. 61
30854935 2020
41
Cadmium and volumetric mammographic density: A cross-sectional study in Polish women. 61
32433664 2020
42
Serum Levels of Commonly Detected Persistent Organic Pollutants and Per- and Polyfluoroalkyl Substances (PFASs) and Mammographic Density in Postmenopausal Women. 61
31963577 2020
43
Measurement challenge: protocol for international case-control comparison of mammographic measures that predict breast cancer risk. 61
31892647 2019
44
Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer. 61
31888552 2019
45
Change in mammographic density across birth cohorts of Dutch breast cancer screening participants. 61
30762225 2019
46
Mammographic Density and Screening Sensitivity, Breast Cancer Incidence and Associated Risk Factors in Danish Breast Cancer Screening. 61
31752353 2019
47
Are mammographic density phenotypes associated with breast cancer treatment response and clinical outcomes? A systematic review and meta-analysis. 61
31352313 2019
48
Genome-wide association study of peripheral blood DNA methylation and conventional mammographic density measures. 61
30694562 2019
49
DNA methylation-based biological age, genome-wide average DNA methylation, and conventional breast cancer risk factors. 61
31636290 2019
50
Obesity-Associated Extracellular Matrix Remodeling Promotes a Macrophage Phenotype Similar to Tumor-Associated Macrophages. 61
31323189 2019

Variations for Mammographic Density

Expression for Mammographic Density

Search GEO for disease gene expression data for Mammographic Density.

Pathways for Mammographic Density

Pathways related to Mammographic Density according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 CYP1B1 CYP1A1 CYP19A1 CYP17A1 COMT
2
Show member pathways
12.41 PGR IGFBP3 IGF1 ESR1
3
Show member pathways
11.7 PRL PGR ESR1
4
Show member pathways
11.62 CYP1B1 CYP1A1 CYP19A1
5
Show member pathways
11.58 HSD17B1 CYP19A1 CYP17A1
6
Show member pathways
11.39 HSD17B1 CYP1A1 CYP19A1 CYP17A1 COMT
7 11.26 ESR1 CYP1B1 CYP1A1
8
Show member pathways
11.26 HSD17B1 CYP1B1 CYP1A1 CYP19A1 CYP17A1 COMT
9
Show member pathways
11.09 HSD17B1 CYP1B1 CYP1A1 CYP19A1 COMT
10 11.06 PGR CYP19A1
11
Show member pathways
10.89 HSD17B1 CYP17A1
12 10.86 IGFBP3 IGF1
13 10.81 IGF1 HSD17B1 CYP1B1 CYP1A1 CYP19A1 CYP17A1
14 10.66 ESR1 CYP1B1 CYP1A1
15 10.13 HSD17B1 CYP19A1
16 10.1 HSD17B1 ESR1 CYP19A1

GO Terms for Mammographic Density

Cellular components related to Mammographic Density according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intracellular membrane-bounded organelle GO:0043231 9.65 CYP1B1 CYP1A1 CYP19A1 CYP17A1 COMT
2 insulin-like growth factor ternary complex GO:0042567 9.16 IGFBP3 IGF1
3 insulin-like growth factor binding protein complex GO:0016942 8.96 IGFBP3 IGF1
4 organelle membrane GO:0031090 8.92 CYP1B1 CYP1A1 CYP19A1 CYP17A1

Biological processes related to Mammographic Density according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.77 HSD17B1 CYP1B1 CYP1A1 CYP19A1 CYP17A1
2 steroid metabolic process GO:0008202 9.65 CYP1B1 CYP1A1 CYP17A1
3 negative regulation of smooth muscle cell proliferation GO:0048662 9.57 IGFBP3 COMT
4 positive regulation of JAK-STAT cascade GO:0046427 9.56 PRL CYP1B1
5 regulation of multicellular organism growth GO:0040014 9.55 PRL IGF1
6 sterol metabolic process GO:0016125 9.54 CYP1B1 CYP19A1
7 epoxygenase P450 pathway GO:0019373 9.52 CYP1B1 CYP1A1
8 uterus development GO:0060065 9.51 ESR1 CYP19A1
9 androgen metabolic process GO:0008209 9.49 ESR1 CYP19A1
10 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.46 IGFBP3 IGF1
11 estrogen biosynthetic process GO:0006703 9.43 HSD17B1 CYP19A1
12 omega-hydroxylase P450 pathway GO:0097267 9.4 CYP1B1 CYP1A1
13 mammary gland development GO:0030879 9.33 PRL PGR CYP19A1
14 toxin metabolic process GO:0009404 9.32 CYP1B1 CYP1A1
15 testosterone biosynthetic process GO:0061370 9.26 HSD17B1 CYP19A1
16 steroid biosynthetic process GO:0006694 9.26 HSD17B1 CYP1A1 CYP19A1 CYP17A1
17 estrogen metabolic process GO:0008210 8.92 HSD17B1 CYP1B1 CYP1A1 COMT

Molecular functions related to Mammographic Density according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 10.1 PGR IGFBP3 ESR1 CYP1B1 CYP1A1 CYP19A1
2 oxidoreductase activity GO:0016491 9.85 HSD17B1 CYP1B1 CYP1A1 CYP19A1 CYP17A1
3 heme binding GO:0020037 9.71 CYP1B1 CYP1A1 CYP19A1 CYP17A1
4 lyase activity GO:0016829 9.69 CYP1B1 CYP1A1 CYP17A1
5 iron ion binding GO:0005506 9.67 CYP1B1 CYP1A1 CYP19A1 CYP17A1
6 steroid binding GO:0005496 9.61 PGR HSD17B1 ESR1
7 steroid hydroxylase activity GO:0008395 9.52 CYP1A1 CYP19A1
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.5 CYP1B1 CYP1A1 CYP19A1
9 estrogen 16-alpha-hydroxylase activity GO:0101020 9.48 CYP1B1 CYP1A1
10 monooxygenase activity GO:0004497 9.46 CYP1B1 CYP1A1 CYP19A1 CYP17A1
11 aromatase activity GO:0070330 9.43 CYP1B1 CYP1A1 CYP19A1
12 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.26 CYP1B1 CYP1A1 CYP19A1 CYP17A1
13 oxygen binding GO:0019825 8.92 CYP1B1 CYP1A1 CYP19A1 CYP17A1

Sources for Mammographic Density

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....